Literature DB >> 26148662

Reduced Toxicity Conditioning and Allogeneic Hematopoietic Progenitor Cell Transplantation for Recessive Dystrophic Epidermolysis Bullosa.

Mark B Geyer1, Kavita Radhakrishnan2, Roger Giller3, Noriko Umegaki4, Sivan Harel4, Maija Kiuru5, Kimberly D Morel6, Nicole LeBoeuf7, Jessica Kandel8, Anna Bruckner9, Sandra Fabricatore10, Mei Chen11, David Woodley11, John McGrath12, LeeAnn Baxter-Lowe13, Jouni Uitto14, Angela M Christiano15, Mitchell S Cairo16.   

Abstract

Recessive dystrophic epidermolysis bullosa is a severe, incurable, inherited blistering disease caused by COL7A1 mutations. Emerging evidence suggests hematopoietic progenitor cells (HPCs) can be reprogrammed into skin; HPC-derived cells can restore COL7 expression in COL7-deficient mice. We report two children with recessive dystrophic epidermolysis bullosa treated with reduced-toxicity conditioning and HLA-matched HPC transplantation.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26148662     DOI： 10.1016/j.jpeds.2015.05.051

Source DB:  PubMed          Journal:  J Pediatr        ISSN： 0022-3476            Impact factor:   4.406


  10 in total

Review 1.  Inside out: regenerative medicine for recessive dystrophic epidermolysis bullosa.

Authors:  Michael Vanden Oever; Kirk Twaroski; Mark J Osborn; John E Wagner; Jakub Tolar
Journal:  Pediatr Res       Date:  2017-11-01       Impact factor: 3.756

2.  Bone marrow transplant with post-transplant cyclophosphamide for recessive dystrophic epidermolysis bullosa expands the related donor pool and permits tolerance of nonhaematopoietic cellular grafts.

Authors:  C L Ebens; J A McGrath; K Tamai; A Hovnanian; J E Wagner; M J Riddle; D R Keene; T E DeFor; R Tryon; M Chen; D T Woodley; K Hook; J Tolar
Journal:  Br J Dermatol       Date:  2019-06-28       Impact factor: 9.302

3.  Fludarabine modulates expression of type VII collagen during haematopoietic stem cell transplantation for recessive dystrophic epidermolysis bullosa.

Authors:  M Vanden Oever; D Muldoon; W Mathews; J Tolar
Journal:  Br J Dermatol       Date:  2021-03-08       Impact factor: 11.113

4.  Future applications of 3D bioprinting: A promising technology for treating recessive dystrophic epidermolysis bullosa.

Authors:  Courtney M Popp; William C Miller; Cindy R Eide; Jakub Tolar
Journal:  Exp Dermatol       Date:  2021-11-07       Impact factor: 4.511

Review 5.  Epidermolysis bullosa: Advances in research and treatment.

Authors:  Christine Prodinger; Julia Reichelt; Johann W Bauer; Martin Laimer
Journal:  Exp Dermatol       Date:  2019-08-08       Impact factor: 3.960

Review 6.  Investigational Treatments for Epidermolysis Bullosa.

Authors:  Ping-Chen Hou; Han-Tang Wang; Stasha Abhee; Wei-Ting Tu; John A McGrath; Chao-Kai Hsu
Journal:  Am J Clin Dermatol       Date:  2021-07-22       Impact factor: 7.403

Review 7.  Progress toward Treatment and Cure of Epidermolysis Bullosa: Summary of the DEBRA International Research Symposium EB2015.

Authors:  Jouni Uitto; Leena Bruckner-Tuderman; Angela M Christiano; John A McGrath; Cristina Has; Andrew P South; Brett Kopelan; E Clare Robinson
Journal:  J Invest Dermatol       Date:  2016-02       Impact factor: 8.551

8.  Efficacy of Human Placental-Derived Stem Cells in Collagen VII Knockout (Recessive Dystrophic Epidermolysis Bullosa) Animal Model.

Authors:  Yanling Liao; Larisa Ivanova; Rajarajeswari Sivalenka; Trevor Plumer; Hongwen Zhu; Xiaokui Zhang; Angela M Christiano; John A McGrath; Jodi P Gurney; Mitchell S Cairo
Journal:  Stem Cells Transl Med       Date:  2018-05-10       Impact factor: 6.940

Review 9.  Revertant Mosaicism in Epidermolysis Bullosa.

Authors:  Cameron Meyer-Mueller; Mark J Osborn; Jakub Tolar; Christina Boull; Christen L Ebens
Journal:  Biomedicines       Date:  2022-01-06

10.  Translational perspectives to treat Epidermolysis bullosa-Where do we stand?

Authors:  Christine Prodinger; Johann W Bauer; Martin Laimer
Journal:  Exp Dermatol       Date:  2020-11       Impact factor: 4.511
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.